Immune checkpoint inhibitor

Nivolumab

Opdivo PD-1 inhibitor immunotherapy

Used in several solid tumors and blood cancers depending on cancer type, stage, and prior treatment.

Biomarker and testing questions

Ask whether PD-L1, MSI-H, dMMR, TMB, or combination immunotherapy questions apply.

Second-opinion questions

Why is immunotherapy recommended now, and should another pathology or biomarker review change the plan?

Safety discussion reminder

Immune-related side effects can be serious. Patients should follow the treating oncology team's monitoring instructions.

Official source links

NCI cancer drug information (NCI)
DailyMed label search (DailyMed)
FDA label search (FDA)
ClinicalTrials.gov search (ClinicalTrials.gov)

Need help turning this into questions?

Ask AI can help organize medicine, biomarker, and treatment-plan questions before you talk with your oncology team.

Ask AI Back to medicines